Successful induction of remission with rituximab for relapse of ANCA-associated vasculitis post-kidney transplant: Report of two cases

American Journal of Transplantation

Volumn 7, Issue 12, 2007, Pages 2821-2825

  Geetha, D ^a   Seo, P ^a   Specks, U ^b   Fervenza, F C ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

ANCA; Kidney; Rituximab; Transplant; Vasculitis

Indexed keywords

CYCLOPHOSPHAMIDE; GLUCOCORTICOID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; B LYMPHOCYTE; CASE REPORT; DRUG DOSE REDUCTION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKOPENIA; MALE; MORBIDITY; PRIORITY JOURNAL; RELAPSE; REMISSION; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; RECURRENCE; REMISSION INDUCTION; VASCULITIS;

EID: 35748938217     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.01985.x     Document Type: Article

References (36)

1. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994 37 : 187 192.
2. Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996 7 : 33 39.
3. Allen A, Pusey C, Gaskin G. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 1998 9 : 1258 1263.
4. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998 9 : 842 852.
5. Lyons GW, Lindsay WG. Renal transplantation in a patient with Wegener's granulomatosis. Am J Surg 1972 124 : 104 107.
6. Steinman TI, Jaffe BF, Monaco AP, Wolff SM, Fauci AS. Recurrence of Wegener's granulomatosis after kidney transplantation. Successful re-induction of remission with cyclophosphamide. Am J Med 1980 68 : 458 460.
7. Nachman PH, Segelmark M, Westman K et al. Recurrent ANCA-associated small vessel vasculitis after transplantation: A pooled analysis. Kidney Int 1999 56 : 1544 1550.
8. Moroni G, Torri A, Gallelli B et al. The Long-Term Prognosis of renal transplant in patients with systemic vasculitis. Am J Transplant 2007 7 : 2133 2139.
9. Gera M, Griffin MD, Specks U, Leung N, Stegall MD, Fervenza FC. Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression. Kidney Int 2007 71 : 1296 1301.
10. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med 1992 116 : 488 498.
11. Martin F, Chan AC. Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 2004 20 : 517 527.
12. Huugen D, Tervaert JW, Heeringa P. Antineutrophil cytoplasmic autoantibodies and pathophysiology: New insights from animal models. Curr Opin Rheumatol 2004 16 : 4 8.
13. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994 83 : 435 445.
14. Salama AD, Pusey CD. Drug insight: Rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2006 2 : 221 230.
15. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005 52 : 262 268.
16. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: Report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006 173 : 180 187.
17. Deegens JK, Artz MA, Hoitsma AJ, Wetzels JF. Outcome of renal transplantation in patients with pauci-immune small vessel vasculitis or anti-GBM disease. Clin Nephrol 2003 59 : 1 9.
18. Curtis JJ, Diethelm AG, Herrera GA, Crowell WT, Whelchel JD. Recurrence of Wegener's granulomatosis in a cadaver renal allograft. Transplantation 1983 36 : 452 454.
19. Reaich D, Cooper N, Main J. Rapid catastrophic onset of Wegener's granulomatosis in a renal transplant. Nephron 1994 67 : 354 357.
20. Fan SL, Lewis KE, Ball E, Dodd S, Raftery MJ, Yaqoob MM. Recurrence of Wegener's granulomatosis 13 years after renal transplantation. Am J Kidney Dis 2001 38 : E32.
21. Rich LM, Piering WF. Ureteral stenosis due to recurrent Wegener's granulomatosis after kidney transplantation. J Am Soc Nephrol 1994 4 : 1516 1521.
22. Mathieson PW, Lockwood CM, Oliveira DB. T and B cell responses to neutrophil cytoplasmic antigens in systemic vasculitis. Clin Immunol Immunopathol 1992 63 : 135 141.
23. Clayton AR, Savage CO. Production of antineutrophil cytoplasm antibodies derived from circulating B cells in patients with systemic vasculitis. Clin Exp Immunol 2003 132 : 174 179.
24. William J, Euler C, Shlomchik MJ. Short-lived plasmablasts dominate the early spontaneous rheumatoid factor response: Differentiation pathways, hypermutating cell types, and affinity maturation outside the germinal center. J Immunol 2005 174 : 6879 6887.
25. Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006 45 : 1432 1436.
26. Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: Favourable but temporary response. Scand J Rheumatol 2005 34 : 229 232.
27. Aries PM, Hellmich B, Voswinkel J et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006 65 : 853 858.
28. Keogh KA, Fervenza FC, Specks U. Rituximab in refractory Wegener's granulomatosis: Favorable or not Am J Respir Crit Care Med 2006 173 : 816.
29. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004 350 : 2572 2581.
30. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006 54 : 2970 2982.
31. Hainsworth JD. Safety of rituximab in the treatment of B cell malignancies: Implications for rheumatoid arthritis. Arthritis Res Ther 2003 5 (Suppl 4 S12 S16.
32. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998 16 : 2825 2833.
33. Hauser AE, Muehlinghaus G, Manz RA et al. Long-lived plasma cells in immunity and inflammation. Ann N Y Acad Sci 2003 987 : 266 269.
34. http://www.fda.gov/fdac/departs/2007/207_update.html rituxan.
35. Itoh K, Kano T, Nagashio C, Mimori A, Kinoshita M, Sumiya M. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus. Arthritis Rheum 2006 54 : 1020 1022.
36. Choy DS, Weiss A, Lin PT. Progressive multifocal leukoencephalopathy following treatment for Wegener's granulomatosis. JAMA 1992 268 : 600 601.